Combining Photothermal Therapy with A NanohybridBased Drug Delivery Strategy for Slow-Released Doxorubicin: A Treatment for Hepatocellular Carcinoma

نویسندگان

چکیده

Background: Hepatocellular carcinoma (HCC) is the fifth most common malignancy in world. Surgical intervention remains primary treatment option for resectable liver cancer. However, low curative resection ratio, high metastatic and risk of recurrence make this less than ideal. Additionally, choice transplantation limited by availability donors. This literature review aimed to discuss combination strategy photothermal therapy nanohybrid-based chemotherapy delivery, which are expected address challenges HCC treatment. Methods: We conducted searches Pubmed, Scopus, ProQuest, Google Scholar using combined keywords such as “hepatocellular carcinoma”, “polyethylene glycol”, “doxorubicin”, “mesoporous silica”, “CuS”, “nanoparticle”, “photothermal therapy”. Based on assessment validity applicability aspects modified Oxford CEBM (Center Evidence-Based Management) OHAT (Office Health Assessment Translation) checklist tools preclinical studies, all selected studies fulfilled eligibility criteria. Results: Photothermal promotes necrosis apoptosis cells ‘heating’ cancer cells. Meanwhile, agent doxorubicin, with mesoporous silica nanohybrids encapsulated copper sulfate polyethylene glycol (PEG-DOX-MSN-CuS), enhances efficiency duration drug circulation blood, reduces clearance, minimizes retention reticuloendothelial system. By utilizing near-infrared light induction from therapy, doxorubicin can be slowly released, leading significantly improved effectiveness. In vitro have demonstrated that achieves over 90% cell death at a concentration 80 µg/mL, conjunction induction. The optimal release time was recored concise 20 minutes. Conclusions: Given numerous benefits associated strategies, PEG-DOX-MSN-CuS holds significant promising HCC.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Au Nanoparticle Loaded with 6-Thioguanine Anticancer Drug as a New Strategy for Drug Delivery

In this study we suggested a new strategy for drug delivery of 6-thioguanine (6-TG) as a cancer drug by loading of this thiolic drug at a surface of Au nanoparticles. For this goal, we synthesized Au nanoparticle (Au/NPs) by reduction of tetrachloroauric (III) acid solutions by sodium borohydride and characterized Au/NPs by X-ray powder diffraction (XRD), dynamic light scattering (DLS), Ultravi...

متن کامل

Preclinical studies of 166Ho-chitosan for treatment of hepatocellular carcinoma

Introduction: Recently, due to the special characteristics of 166Ho and chitosan, 166Ho-chitosan complex was developed for treatment of tumors such as hepatocellular carcinoma. This complex has been lately prepared with high radiochemical purity in our lab. The preclinical studies of the complex however should be performed to evaluate the tracer concentration in target and...

متن کامل

Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma

BACKGROUND N-lactosyl-dioleoylphosphatidylethanolamine (Lac-DOPE) was synthesized and evaluated as a liver-specific targeting ligand via asialoglycoprotein receptors for liposomal delivery of doxorubicin. METHODS Lactosylated liposomes encapsulating calcein (Lac-L-calcein) or doxorubicin (Lac-L-DOX) composed of egg phosphatidylcholine, cholesterol, monomethoxy polyethylene glycol 2000-distear...

متن کامل

Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is the most common primary liver cancer with high morbidity and mortality worldwide. Chemotherapy is recommended to patients with intermediate or advanced stage cancer. However, the conventional chemotherapy yields low desired response rates due to multidrug resistance, fast clearance rate, nonspecific delivery, severe side effects, low drug concentration in cance...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Indonesian Journal of Cancer

سال: 2023

ISSN: ['2355-6811']

DOI: https://doi.org/10.33371/ijoc.v17i2.964